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The last two decades have witnessed radical changes in the 
treatment for inflammatory bowel disease (IBD), with an 
explosion of monoclonal antibody-based ‘biologic’ drugs 
targeting components of the immune system. As a conse-
quence, treatment strategies have rapidly evolved, aiming at 
increasingly ambitious targets.
Despite these major advances, therapy remains far from 
optimal since achieving and maintaining remission contin-
ues to be challenging in many patients. Thus, since IBD 
treatment can be far from satisfactory for both physicians 
and patients, it is not surprising that translational and clinical 
investigation is focused on intestinal inflammation.
Though there is a great interest in developing new drugs 
and exploiting novel mechanisms to treat IBD, the major-
ity of IBD patients suffer from mild-to-moderately active 
disease that does not require more aggressive, costly, and 
potentially harmful therapy. In these cases, significant efforts 
should also be made in order to improve and maximize the 
efficacy of already available therapies. For example, mol-
ecules with low systemic impact such as 5-aminosalicylates 
and low-bioavailability topical corticosteroids act directly on 
inflamed mucosa without achieving significant concentra-
tions in the systemic circulation; these drugs greatly benefit 
from different administration routes, formulations, and drug 
delivery systems, which enhance the exposure of therapeutic 
molecules to the diseased sites.
Moreover, in ulcerative colitis patients needing stronger 
treatments, topical therapies are important adjunctive treat-
ments since symptoms related to distal inflammation (e.g., 
urgency, tenesmus, incontinence, soiling) significantly 
worsen quality-of-life. Nevertheless, several factors, such 
as retention problems, unpleasant feeling, rectal/abdominal 
pain, and flatulence, may limit the adherence to rectal thera-
pies. As a consequence, more comfortable and acceptable 
topical formulations are welcome in order to further improve 
adherence with consequent increased efficacy.
Budesonide is a synthetic nonhalogenated glucocorticoid 
related to triamcinolone hexacetonide, developed in order 
to reduce systemic side effects from steroids. Oral formula-
tions of budesonide are used in mild-to-moderately active 
Crohn’s disease and ulcerative colitis. Indeed, clinical trials 
demonstrated the efficacy and safety of topical budesonide 
formulations in treating active distal forms of IBD, namely 
ulcerative colitis [1]. Since budesonide foams, it is preferred 
over enemas by patients [2] and at present is used in several 
countries.
Although comparative studies historically showed that 
topical corticosteroids are less effective than topical mesa-
lamine when treating active ulcerative colitis [3], some stud-
ies showed similar efficacy between rectal budesonide and 
rectal 5-ASA [4, 5]. As such, given the theoretical superior 
anti-inflammatory potency of corticosteroid molecules, it is 
plausible that there may be room for improvement through 
optimization of their efficacy. In particular, since effective-
ness and tolerability of topical therapy mainly resides in the 
features of its formulation, attention should focus on identi-
fying different drug release modalities. Indeed, rheological 
qualities of the rectal formulations strongly influence the 
time of exposure of the mucosa to the therapeutic molecules, 
the extent of the colon that can be reached, number of daily 
administrations, retention time, and patient discomfort.
In this issue of Digestive Diseases and Sciences, Lazaro 
et al. [6] evaluated the effects of a novel formulation of 
topical budesonide in a chemically induced mice model of 
colitis. In detail, they used an inclusion complex of bude-
sonide/hydroxypropyl-beta-cyclodextrin, a formulation 
that increases drug solubility, incorporated in poloxamer 
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hydrogels; interestingly, the suspension resulting from the 
incorporation of cyclodextrin into poloxamer-based gels 
possesses the capacity to change its physical state and quali-
ties in response to minor temperature variations. At room 
temperature, the suspension is a liquid, and, thus, when 
administered as enema, can easily ascend proximally and 
reach the splenic flexure. On the other hand, at physiologi-
cal body temperature, the mixture becomes semisolid, thus 
easier to retain, persistently adhering to the colonic mucosa, 
enhancing exposure time to the therapeutic compounds. Fur-
thermore, the formation of drug-containing micelles leads 
to micelle–micelle interactions that support persistent drug 
release. The authors analyzed weight loss, tissue myeloper-
oxidase activity, macroscopic and microscopic inflamma-
tory activity, pro-inflammatory cytokine expression (TNF 
and interleukin-1β), and inhibition of endogenous steroid 
production in a rat IBD model. Results demonstrated that 
the incorporation of budesonide into poloxamer hydrogels 
was superior to plain or hydroxypropyl-beta-cyclodextrin-
included budesonide in the reduction of intestinal inflam-
mation; indeed, the administration of poloxamer hydrogels 
alone, without budesonide, quite surprisingly showed a trend 
toward a better efficacy than the control budesonide formu-
lations, suggesting that poloxamer hydrogels might possess 
anti-inflammatory properties in and of themselves.
In recent years, several new different budesonide topi-
cal formulations have been proposed in preclinical studies 
conducted in animal models [7, 8]. In particular, a formu-
lation with similar rheological properties to the compound 
studied by Lazaro et al. (thermosensitive drug delivery 
platform, based on hydrophilic polyethylene glycol hydro-
phobic polypropylene glycol blocks) has been described 
and tested in murine dextran sodium sulfate chemically 
induced colitis; likewise, this formulation proved to 
be superior to liquid budesonide in controlling colonic 
inflammation [8]. Still, the interest and novelty of the data 
presented in this issue of Digestive Diseases and Sciences 
remain very high; in fact, this approach, if translated to 
IBD patients, holds the potential to significantly enhance 
the effectiveness of topical therapies and may theoretically 
be applied to other topical drugs, not only mesalamine 
and beclomethasone dipropionate, but also inhibitors of 
tumor necrosis factor-alpha or other cytokines, as well. 
Still, although results have to be confirmed in humans 
by means of phase 1 clinical studies, translation to IBD 
patients may not be as linear as expected; indeed, chemi-
cally induced models of colitis may not fully recapitulate 
human disease, due to the marked differences between all 
experimental IBD models and human disease. Moreover, 
factors such as discomfort in auto-administering rectal 
therapies and compliance and adherence, together with 
the extent of colon reached by the enema/foam, which are 
pivotal elements in managing human disease, cannot be 
accurately predicted in preclinical studies conducted on 
animal models. Nonetheless, Lazaro’s manuscript strongly 
paves the way to future clinical studies.
The discovery and introduction in clinical practice 
of novel therapeutic agents have always marked excit-
ing moments in the history of IBD therapy. Despite vast 
resources spent by pharmaceutical companies in order to 
launch new drugs with innovative mechanisms of action, 
in the era preceding the introduction of biologic IBD 
therapies, substantial progress was made by improving 
existing drug formulations. Perfecting drug formulations 
enables the more efficient targeting the anatomical site of 
the disease, prolongation of drug exposure time, and the 
reduction in the amounts of therapeutic molecules reach-
ing nontarget systems or organs, thus reducing adverse 
effects. Since this type of therapeutic optimization remains 
of utmost importance, it is reassuring that this type of 
work remains important for researchers and pharmaceuti-
cal companies.
Since IBD is a lifelong disease, any drug may lose its 
efficacy over time. While looking for new, potent, and 
groundbreaking weapons in the therapeutic arsenal, clini-
cians should not lose sight of proven therapies, constantly 
endeavoring to find innovative ways to employ them.
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